Clinical Trials

JPMorgan Chase Co. acquired a new position in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 146,767 shares of the company’s stock, valued at approximately $1,865,000. JPMorgan Chase Co. owned about 0.70% of Zynerba Pharmaceuticals as of its most […]

by

Experimental surgery: Seizure control can make an enormous difference to autistic people’s lives, regardless of its impact on diagnosis. Put simply, “seizures cause neuronal firing, and that can drown out or derail normal development of the brain,” says Anne Berg, research professor of pediatrics at Northwestern University in Chicago, Illinois. In a 2017 study, Ghatan and […]

by

Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel. The shares were weak lately as the stock has fallen over 17% in the past month and over 31% in the past three months. Investors remained concerned about the company’s future and raised […]

by

Published in the Journal of Clinical Investigation, the research conducted using Angelman syndrome animal models shows that CBD could benefit kids and adults with this serious condition, which is characterized by intellectual disability, lack of speech, brain rhythm dysfunction, and deleterious and often drug-resistant epilepsy. “There is an unmet need for better treatments for kids […]

by

Posted in: Medical Science News | Medical Research News | Medical Condition News Tags: Angelman Syndrome, Anxiety, Brain, Cannabidiol, Cannabis, Cell, Cell Biology, Clinical Trial, Disability, Efficacy, Epilepsy, Medicine, Neuroscience, Pain, Physiology, Preclinical, Research, Seizure, Sleep, Speech … read more at: https://www.news-medical.net/news/20190918/Cannabidiol-may-alleviate-seizures-and-normalize-brain-rhythms-in-Angelman-syndrome.aspx

by

Patients have been left wondering how they can access medicinal cannabis in Australia…until now. Despite the Australian government approving the use of cannabis for medical purposes close to three years ago, there is still some red tape in the way of Australians getting access to the drug. A lot of the information out there can […]

by

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. Risk Volatility Zynerba Pharmaceuticals has a beta of 4.79, meaning that its share price is […]

by

Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability. Risk Volatility Zynerba Pharmaceuticals has a beta of 4.79, meaning that its share price is […]

by

Atika Capital Management Llc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 116% based on its latest 2019Q2 regulatory filing with the SEC. Atika Capital Management Llc bought 29,000 shares as the company’s stock declined 2.22% . The hedge fund held 54,000 shares of the major pharmaceuticals company at the end of 2019Q2, valued […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) have received an average recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have […]

by

Jefferies Financial Group reaffirmed their hold rating on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) in a report issued on Monday, BenzingaRatingsTable reports. Jefferies Financial Group currently has a $11.00 price target on the stock. Other research analysts have also issued reports about the stock. ValuEngine lowered shares of Zynerba Pharmaceuticals from a buy rating to a […]

by

Cetera Investment Advisers purchased a new position in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,800 shares of the company’s stock, valued at approximately $151,000. A number of other institutional investors and hedge funds also recently modified their holdings […]

by